Na-yiyuan Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/115944/publications.pdf Version: 2024-02-01



Να-νινιτανι Μ/Π

#	Article	IF	CITATIONS
1	MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Scientific Reports, 2017, 7, 40384.	3.3	73
2	Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells. Cell Reports, 2017, 18, 2557-2565.	6.4	61
3	Mechanism-based inhibition of Alantolactone on human cytochrome P450 3A4 in vitro and activity of hepatic cytochrome P450 in mice. Journal of Ethnopharmacology, 2015, 168, 146-149.	4.1	21
4	Genetic variation of CYP3A5 influences paclitaxel/carboplatinâ€induced toxicity in Chinese epithelial ovarian cancer patients. Journal of Clinical Pharmacology, 2016, 56, 349-354.	2.0	18
5	Ageâ€related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinumâ€based chemotherapy. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 21-29.	1.9	18
6	Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. Journal of Thoracic Disease, 2018, 10, 3329-3340.	1.4	12
7	SOX1 and PAX1 Are Hypermethylated in Cervical Adenocarcinoma and Associated with Better Prognosis. BioMed Research International, 2020, 2020, 1-8.	1.9	5
8	Genetic variation of rs12918566 affects GRIN2A expression and is associated with spontaneous movement response during sevoflurane anesthesia induction. Brain and Behavior, 2021, 11, e02165.	2.2	3